These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30257247)

  • 1. The Future: Experimental Therapies for Renal Disease in Diabetes.
    Fouli GE; Gnudi L
    Nephron; 2019; 143(1):3-7. PubMed ID: 30257247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
    Leehey DJ
    Kidney360; 2020 Apr; 1(4):292-299. PubMed ID: 35372914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Barrera-Chimal J; Jaisser F
    Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibition to address the unmet needs in diabetic nephropathy.
    Barutta F; Bernardi S; Gargiulo G; Durazzo M; Gruden G
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3171. PubMed ID: 30997935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
    Block TJ; Batu D; Cooper ME
    Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies.
    Warren AM; Knudsen ST; Cooper ME
    Expert Opin Ther Targets; 2019 Jul; 23(7):579-591. PubMed ID: 31154867
    [No Abstract]   [Full Text] [Related]  

  • 7. New hypoglycemic agents and the kidney: what do the major trials tell us?
    Smyth B; Perkovic V
    F1000Res; 2018; 7():. PubMed ID: 30542615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy.
    Elmarakby AA; Sullivan JC
    Cardiovasc Ther; 2012 Feb; 30(1):49-59. PubMed ID: 20718759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
    Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
    Sourris KC; Yao H; Jerums G; Cooper ME; Ekinci EI; Coughlan MT
    Curr Drug Targets; 2016; 17(11):1252-64. PubMed ID: 26201485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes.
    De Nicola L; Gabbai FB; Liberti ME; Sagliocca A; Conte G; Minutolo R
    Am J Kidney Dis; 2014 Jul; 64(1):16-24. PubMed ID: 24673844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies in diabetic nephropathy: an update.
    Gupta A; Gupta P; Biyani M
    J Nephrol; 2011; 24(6):686-95. PubMed ID: 22058027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis.
    Ojima A; Matsui T; Nishino Y; Nakamura N; Yamagishi S
    Horm Metab Res; 2015 Aug; 47(9):686-92. PubMed ID: 25611208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
    Mima A
    J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.
    Garofalo C; Borrelli S; Liberti ME; Andreucci M; Conte G; Minutolo R; Provenzano M; De Nicola L
    Medicina (Kaunas); 2019 Jun; 55(6):. PubMed ID: 31212638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapies on the Horizon for Diabetic Kidney Disease.
    Khan SS; Quaggin SE
    Curr Diab Rep; 2015 Dec; 15(12):111. PubMed ID: 26458382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huangkui capsule attenuates renal fibrosis in diabetic nephropathy rats through regulating oxidative stress and p38MAPK/Akt pathways, compared to α-lipoic acid.
    Mao ZM; Shen SM; Wan YG; Sun W; Chen HL; Huang MM; Yang JJ; Wu W; Tang HT; Tang RM
    J Ethnopharmacol; 2015 Sep; 173():256-65. PubMed ID: 26226437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.
    Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Chattipakorn SC; Chattipakorn N; Lungkaphin A
    Biomed Pharmacother; 2017 Oct; 94():176-187. PubMed ID: 28759755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.